Healthcare Industry News: bifurcation
News Release - May 21, 2007
OrbusNeich Receives CE Mark Approval for Blazer(TM) Cobalt Chromium Stent, Sapphire(TM) PTCA Dilatation Catheter, Lumina(TM) Guiding Catheter
Company Expands Portfolio of Interventional Cardiology Products With Emphasis on Design InnovationHONG KONG, May 21 (HSMN NewsFeed) -- OrbusNeich today announced that it has received CE Mark approval for three interventional cardiology products: the Blazer cobalt chromium stent, the Sapphire PTCA dilatation catheter and the Lumina 6F guiding catheter.
With its unique dual helix design and thin cobalt chromium stent struts, Blazer enables physicians to overcome the flexibility challenges associated with the slotted tube construction of most stents. In addition, Blazer provides unsurpassed sidebranchability of up to 4.5 mm for effective bifurcation stenting and for maintaining the patency of side branches.
Sapphire is a balloon that combines several advanced technologies to provide ultimate crossability. The soft, tapered Sunflex tip is engineered for smooth lesion accessibility and ultra-low tip profile. With a specially formulated Slidematrix dual coating and the enhanced Tight Fold (TiFo) processing, Sapphire is ideal for lubricious crossing.
Lumina is a catheter with a wide inner body -- 0.071" diameter -- that enables the passage of multiple devices and provides excellent visualization during procedures. Lumina's hybrid flat/round wire braid design and Quad system technology provide increased pushability, enhanced torque control, excellent back-up support and optimal overall performance.
"We're continuing to expand our portfolio of interventional cardiology products with an emphasis on design innovation," said Samuel Rasmussen, OrbusNeich's president and CEO. "The unique design and composition of our wide range of products are the hallmarks of OrbusNeich and provide physicians with flexible solutions for their cases."
OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer, R stent(TM), Sapphire, Avita(TM), Avita HP(TM), SafeCut(TM), Lumina and Saffron.
A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, supplies products in more than 60 countries. For more information, visit www.OrbusNeich.com.
Source: OrbusNeich
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
